Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis

被引:0
作者
Kenji Omae
Tsunenori Kondo
Takafumi Kennoki
Toshio Takagi
Junpei Iizuka
Hirohito Kobayashi
Yasunobu Hashimoto
Kazunari Tanabe
机构
[1] Tokyo Women’s Medical University,Department of Urology
来源
International Journal of Clinical Oncology | 2016年 / 21卷
关键词
Renal cancer; End-stage renal disease; Prognosis; Survival; Biomarker;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:126 / 132
页数:6
相关论文
共 108 条
  • [1] Ishikawa I(1990)Ten-year prospective study on the development of renal cell carcinoma in dialysis patients Am J Kidney Dis 16 452-458
  • [2] Saito Y(1994)Ultrasonic diagnosis of renal cell carcinoma in hemodialysis patients J Urol 152 846-851
  • [3] Shikura N(2002)Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis Kidney Int 61 2201-2209
  • [4] Terasawa Y(2007)Renal cell carcinoma in transplant recipients with acquired cystic kidney disease Clin J Am Soc Nephrol 2 750-756
  • [5] Suzuki Y(2011)Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population Eur Urol 60 366-373
  • [6] Morita M(2010)Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis BJU Int 105 620-627
  • [7] Denton MD(2013)Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review BMC Nephrol 14 84-134
  • [8] Magee CC(2007)Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125-296
  • [9] Ovuworie C(2002)Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol 20 289-972
  • [10] Schwarz A(2005)Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 965-5480